Evidence map›Paper›PMID 36552044›Full record

ArticleBiomedicines2022

Investigating the Antibacterial Properties of Prospective Scabicides.

Sara Taylor, Deonne Walther, Deepani D Fernando, Pearl Swe-Kay, Katja Fischer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Scabies.Nature reviews. Disease primers · 2024
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sara TaylorInfection and Inflammation Program, Scabies Laboratory, QIMR Berghofer MRI, Brisbane, QLD 4006, Australia.
Deonne WaltherInfection and Inflammation Program, Scabies Laboratory, QIMR Berghofer MRI, Brisbane, QLD 4006, Australia.
Deepani D FernandoInfection and Inflammation Program, Scabies Laboratory, QIMR Berghofer MRI, Brisbane, QLD 4006, Australia.
Pearl Swe-KayInfection and Inflammation Program, Scabies Laboratory, QIMR Berghofer MRI, Brisbane, QLD 4006, Australia.
Katja FischerInfection and Inflammation Program, Scabies Laboratory, QIMR Berghofer MRI, Brisbane, QLD 4006, Australia.ORCID 0000-0003-3408-3337

Funding

DIORAPHTE-funded Research Programme for Skin-related Neglected Tropical Diseases. 20 02 04 03National Health and Medical Research Council APP1154805 and APP1163354
6 · The paper itself

Abstract

Scabies is a dermatological disease found worldwide. Mainly in tropical regions, it is also the cause of significant morbidity and mortality due to its association with potentially severe secondary bacterial infections. Current treatment strategies for scabies do not consider the role of opportunistic bacteria, and here we investigate whether current and emerging scabicides can offer any anti-bacterial protection. Using the broth microdilution method, we examined antimicrobial potential of the current scabicide ivermectin and emerging scabies treatments: abametapir, mānuka oil, and its individual β-triketones. Our results demonstrate that the two novel scabicides abametapir and mānuka oil have antimicrobial properties against common scabies-associated bacteria, specifically

Indexed as

abametapirAcinetobacter baumanniiimpetigoivermectinmānuka oilscabiesStaphylococcus aureusStreptococcus dysgalactiae subsp. equisimilisStreptococcus pyogenesβ-triketones

Identifiers

PMID36552044
PMCPMC9776028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.